Astellas; Cullgen; Roche; AbbVie; Boehringer Ingelheim; Mersana Therapeutics; Aldeyra Therapeutics; Lilly

Astellas; Cullgen; Roche; AbbVie; Boehringer Ingelheim; Mersana Therapeutics; Aldeyra Therapeutics; Lilly

Today in FirstWord Pharma 's Industry News newsletter, we cover:

?? Astellas adds to protein degrader pipeline with Cullgen deal

? Roche gets FDA nod for Columvi in diffuse large B-cell lymphoma

?? Skyrizi succeeds as maintenance in Phase III ulcerative colitis study

?? Mersana hit with FDA partial hold after five deaths in ovarian cancer studies

?? Aldeyra's reproxalap hits main goal of Phase III allergic conjunctivitis study

?? Lilly joins forces with Verve on gene editing therapy targeting Lp(a)

?? To learn more about these top stories, sign up to receive our newsletter ?? https://firstwordpharma.com/register and never miss the important news and insights impacting the #pharma industry!

#pharmaceuticals #biotechnology #news #insights

要查看或添加评论,请登录

FirstWord Pharma的更多文章

社区洞察

其他会员也浏览了